www.taro.com

Trademarks and Copyright© The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Taro to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions.

News Release
<< Back
Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2017

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Jun. 22, 2017-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2017, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section of Taro’s website at www.taro.com.

Hard copies of the report may be ordered free of charge by sending requests to:

Taro Pharmaceuticals U.S.A., Inc.
Three Skyline Drive
Hawthorne, NY 10532
attention: William J. Coote or
via email to William.Coote@Taro.com

Additionally, the report may be accessed on the SEC’s website at www.sec.gov.

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit Taro’s website at www.taro.com.

Source: Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.
Mariano A. Balaguer, 914-345-9001
VP, CFO
Mariano.Balaguer@taro.com
or
William J. Coote, 914-345-9001
AVP, Business Finance, Treasurer and Investor Relations
William.Coote@taro.com

Terms of Use
  |  
Privacy Statement
  |  
Safe Harbor Statement